Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Resapp Health to restart respiratory app study after enhancing its technology

Doctors Without Borders is not proceeding with its evaluation of the app.
A woman coughing
An improved audio recording app will now be deployed

Resapp Health Ltd (ASX:RAP) is planning to restart the U.S. paediatric clinical study of its “ResAppDx” app to detect respiratory diseases, this U.S. winter.

The company’s smartphone app works by using algorithms to analyse the sound of a patient’s cough and provide a diagnosis.

To improve the data-gathering element of the study, ResApp will now be regularly present onsite conducting clinical study team training, reviewing enrolment procedures and verifying data.

This is to help ensure that high-quality cough sounds are collected as early as possible during the patient’s hospital visit and prior to any treatment known to affect cough analysis.

Furthermore, an improved audio recording smartphone application incorporating built-in checklists, automated background noise estimation and additional visual aids will be deployed.

This is to support the data collection teams and eliminate inappropriate collection of cough data with background noise contamination.

However, Doctors Without Borders is not proceeding with its evaluation of ResAppDx, following the review of the issues identified in Resapp’s earlier study and the high cost of keeping the project open.

ResApp and Doctors Without Borders will maintain their collaborative relationship and seek opportunities for field testing the technology once the issues have been resolved.

All sites have reaffirmed their intention to rerun the updated study and are targeting to restart the study before the beginning of the U.S. winter season.

View full RAP profile View Profile

ResApp Health Ltd Timeline

Newswire
April 18 2016

Related Articles

cancer cells
February 10 2017
It has already got £7.2mln of the £14.9mln it is looking to raise, which will help fund the development of two promising cancer drug candidates: RXC004 and RXC005
The Hydroponics Company Ltd issued a cannabis research licence
July 11 2017
The licence allows Canndeo to build its exclusive Plant Breeders Rights.
picture of doctor
September 06 2017
A Phase I clinical trial is to start later this year for the LOXL-2 inhibitor

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use